Economic Burden and Healthcare Costs of COVID-19

The COVID-19 pandemic has imposed unprecedented pressures on health systems and economies worldwide. Direct medical costs—comprising diagnostics, hospitalisation, therapeutics and intensive care—have surged in regions experiencing high caseloads, while indirect costs such as productivity losses, long-term disability and societal disruption have compounded the financial toll. In high-income countries, per-patient hospital costs have often exceeded several thousand pounds, driven by extended lengths of stay, high staffing ratios and advanced respiratory support. In low- and middle-income settings, the reallocation of scarce resources towards pandemic response has strained routine services, leading to deferred care for chronic conditions and subsequent downstream costs. Macroeconomic impacts have included reductions in gross domestic product, interrupted supply chains and labour-market shocks, with service sectors and small enterprises particularly vulnerable to lockdown measures. Economic evaluations of public-health interventions—testing, contact tracing, vaccination and non-pharmaceutical measures—have highlighted the trade-offs between upfront investment and future savings in both health and social domains. A coherent understanding of these cost drivers and their interactions is essential to guide policymakers in balancing pandemic containment with economic resilience and equitable healthcare provision.

Research from Nature Portfolio

Repeated cross-sectional analysis of hospital data in Italy quantified the incremental costs associated with COVID-19 admissions. Median hospitalisation costs rose from €2,410 before the pandemic to €2,645 for SARS-CoV-2-negative cases and €3,834 for positive cases. The greatest cost inflation was observed in patients with non-COVID diagnoses who tested positive, including those with renal infections and intracranial events, reflecting higher resource use across complex comorbidities. This work harnessed diagnosis-related group accounting and regression modelling to isolate pandemic-specific cost increases, providing granular insight into how outbreaks strained hospital budgets and highlighting areas for efficiency gains in future health crises.

Economic Burden and Healthcare Costs of COVID-19 publication trend

The graph below shows the total number of articles in economic burden and healthcare costs of covid-19 across all publications each year (not limited to Nature Index journals).

Technical terms

Direct medical costs: Expenditures for medical services, supplies and treatments directly related to patient care.

Indirect costs: Economic losses due to reduced productivity, absenteeism and long-term disability.

Cost-of-illness (COI) study: An analysis estimating economic burden by quantifying direct and indirect costs associated with a disease.

Micro-costing: A bottom-up approach that itemises and values individual healthcare resources used per patient.

Productivity losses: Economic impact of workdays lost or diminished output resulting from illness or control measures.

References

1. A repeated cross-sectional analysis on the economic impact of SARS-CoV-2 pandemic at the hospital level in Italy. Scientific Reports (2023).
2. The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis. Systematic Reviews (2024).
3. COVID-19 healthcare cost and length of hospital stay in Turkey: retrospective analysis from the first peak of the pandemic. Health Economics Review (2021).